Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22142076 | 0.86 | CHRM2 (0.34) | CHRM2CHRM3TSHRSLC6A1SLC6A13 | |
| SCHEMBL16072912 | 0.79 | TSHR (0.39) | CHRM2CHRM3TSHRSLC6A1SLC6A13 | |
| Hydrochloric Acid SCHEMBL25342137 | 0.77 | BLM (0.41) | CHRM2CHRM3TSHRSLC6A1SLC6A13 | |
| SCHEMBL22142398 | 0.73 | — | — | |
| SCHEMBL22142094 | 0.73 | CHRM2 (0.37) | CHRM2CHRM3TSHRSLC6A1SLC6A13 | |
| SCHEMBL22142077 | 0.73 | CHRM2 (0.37) | CHRM2CHRM3TSHRSLC6A1SLC6A13 | |
| SCHEMBL21422485 | 0.72 | TSHR (0.35) | TSHRBLM | |
| SCHEMBL22488553 | 0.70 | TSHR (0.39) | CHRM3TSHRSLC6A1SLC6A13BLM | |
| Hydrochloric Acid SCHEMBL22468585 | 0.68 | BLM (0.41) | CHRM3TSHRSLC6A1SLC6A13BLM | |
| SCHEMBL18134378 | 0.68 | HTR2C (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | XBP1, RNASE1, ERN1 | CHRM2 4561/4885CHRM3 4048/4885TSHR 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.